New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
11:12 EDTJAZZJazz Pharmaceuticals price target lowered to $151 from $182 at Cantor
Cantor believes an overhang remains on Jazz Pharmaceuticals as the company continues to dispute the wording in the final REMS for Xyrem and the firm now sees a lower chance that the company may be taken over in the next year. Cantor lowered its price target on Jazz to $151 from $182 and maintains its Hold rating on the shares.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
12:19 EDTJAZZJazz Pharmaceuticals management to meet with JMP Securities
Subscribe for More Information
August 20, 2014
09:46 EDTJAZZAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
August 19, 2014
13:28 EDTJAZZJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
10:13 EDTJAZZOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:20 EDTJAZZJazz Pharmaceuticals initiated with an Overweight at JPMorgan
Subscribe for More Information
August 18, 2014
11:41 EDTJAZZCubist rises after report sparks takeover interest speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use